The Biotech View with Michelle Simpson-Abelson, Iovance Therapeutics at Phacilitate Leaders World

The Biotech View with Michelle Simpson-Abelson, Iovance Therapeutics

Episode two of the Phacilitate Leaders World 2020 super plenary series with Michelle Simpson-Abelson, Principle Scientist at Iovance
 
If you want to know more about Iovance’s pipeline and their approach to manufacturing tumour infiltrating lymphocytes this is the interview you need to watch.
 
Michelle discusses the approach to extracting TILs from biopsy tissue, expansion and then the transfer back to patients. With recent clinical repose rates of 36% and 44% for different indications and that’ without reaching the duration of response, this is a really exciting development for the advanced therapies industry.
 
Iovance still has some significant hurdles to overcome, namely a 22-day manufacturing process and the additional complication of gene editing the TILs themselves. However, considering this was once a six-week manufacturing process and Iovance is currently building their own manufacturing capacity, the outlook is optimistic!






More episodes in this series...

The patient's view super plenary at Phacilitate Leaders World 2020
Episode 1
The Patient's View with Joan C. Finnegan




The innovator view, super plenary at Phacilitate Leaders World 2020
Episode 3
The Innovator's View with Jana Stoudemire, Space Tango


 

Episode 4
The KOL's View with Dr Philippe Menasche